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Abstract
Background: Protease inhibitors such as ritonavir can cause nausea and vomiting which is the
most common reason for discontinuation. Rats react to nauseous and emetic stimuli by increasing
their oral intake of non-nutritive substances like kaolin, known as pica behavior. In this study, we
evaluated the effects of methylnaltrexone, a peripherally acting mu-opioid receptor antagonist that
does not affect analgesia, on ritonavir-induced nausea and vomiting in a rat pica model.
Results: We observed that 24 to 48 hr after administration of oral ritonavir 20 mg/kg, kaolin
consumption increased significantly in rats (P < 0.01). This increase was attenuated by pretreatment
with an intraperitoneal injection of methylnaltrexone (0.3–3.0 mg/kg) in a dose dependent manner
(P < 0.01) and also with naloxone (0.1–0.3 mg/kg) (P < 0.01). The areas under the curve for kaolin
intake from time 0 to 120 hr were significantly reduced after administration of the opioid
antagonists. Food intake was not significantly affected. Plasma naltrexone levels were measured
after methylnaltrexone injection, and no detectable levels were found, indicating that
methylnaltrexone was not demethylated in our experimental paradigm.
Conclusion: These results suggest that methylnaltrexone may have potential clinical utility in
reducing nausea and vomiting in HIV patients who take ritonavir.
Introduction
Infection with the human immunodeficiency virus (HIV),
which may progress to acquired immune deficiency syn-
drome (AIDS), is a deadly disease that affects many mil-
lions of people worldwide [1,2]. If patients are not treated
in a timely fashion, the disease can cause morbidity and
lead to death because of immune dysfunction and oppor-
tunistic infections. To reduce viral loads and improve life
expectancy, treatment guidelines require that patients
comply with drug regimens for an extended period of time
[3,4]. The main obstacles to such compliance are treat-
ment-induced adverse effects. Adverse effects not only
deteriorate quality of life, but negatively affect compliance
[5]. Nausea and vomiting are examples of drug-induced
adverse effects that may affect compliance [4,6,7].
Protease inhibitors are commonly used potent anti-HIV
drugs. Drugs in this class, especially ritonavir, induce nau-
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sea and vomiting [8]. Ritonavir is used in anti-HIV therapy
as an adjuvant to other protease inhibitors because it
inhibits the hepatic CYP 3A enzyme, thereby increasing
the bioavailability and plasma concentration of other
antiviral agents [9,10]. Although the dose required for the
adjuvant effects of ritonavir is lower than that required for
its direct antiviral effect, nausea and emesis have been
reported in at least 20% of the patients taking it [4].
In rats, emetic stimuli alter feeding habits, manifested as
pica behavior, i.e., an increased consumption of non-
nutritive substances such as kaolin, a type of clay [11-13].
Using the rat and pica model, we previously quantified
kaolin consumption as a measure of nausea and vomit-
ing. We observed that drug-induced consumption of pica
was decreased by administration of selected pharmaco-
logical agents [14-16].
Methylnaltrexone is a novel peripherally acting mu-opioid
receptor antagonist derived from naltrexone [17] (Fig. 1).
In a previous pilot study in healthy subjects, we observed
that methylnaltrexone decreased certain opioid-induced
troublesome subjective effects, including nausea [18]. In
other studies using the rat pica model, methylnaltrexone
reduced opioid-induced nausea and vomiting [16].
Although the mechanism by which ritonavir causes nau-
sea and vomiting is unknown, combinations of anti-emet-
ics may partially abate the symptoms of ritonavir [19,20].
In this study, we evaluated the effects of methylnaltrexone
on ritonavir-induced nausea and vomiting in the rat pica
model. Naloxone, a non-selective opioid receptor antago-
nist, was also used for comparison with the methylnal-
trexone for effect and site of action.
Methods
Animals
The experimental protocols were approved by the Institu-
tional Animal Care and Use Committee or IACUC of the
University of Chicago. Male Wistar strain rats (Harlan
Sprague Dawley, Indianapolis, IN), weighing between
150–300 g, were housed in environmentally controlled
conditions with a 12 hr light, 12 hr dark cycle. Rats were
allowed free access to water and standard laboratory rat
chow (Harlan-Teklad, Madison, WI).
Measurement of pica (kaolin intake)
Kaolin pellets were prepared based on a method described
previously [15]. Briefly, pharmacological grade kaolin (or
hydrated aluminum silicate; Fisher, Fair Lawn, NJ) and
acacia (or gum arabic; Fisher, Fair Lawn, NJ) were mixed
using a 99:1 ratio in distilled water. The kaolin paste was
rolled and cut into pieces similar in shape to rat chow pel-
lets. The pellets were dried at room temperature for 72 hr.
Rats were placed in individual isolation cages (45 cm × 35
cm × 25 cm) and were allowed access to regular food and
kaolin during a 3-day adaptation period before the study
period. There were 6–7 rats in each of the four groups:
vehicle (saline) plus vehicle, vehicle plus ritonavir,
naloxone plus ritonavir, and methylnaltrexone plus riton-
avir. Rats received ritonavir 20 mg/kg (Abbott Laborato-
ries, North Chicago, IL) orally via a gavage tube in the
morning on 2 consecutive days (0 hr and 24 hr) [21-23].
Vehicle, naloxone 0.1 mg/kg or 0.3 mg/kg (Sigma, St.
Louis, MO), or methylnaltrexone 0.3 mg/kg, 1.0 mg/kg,
or 3.0 mg/kg (Mallinckrodt Chemicals, St. Louis, MO)
pretreatment was administered intraperitoneally [15], 30
min before 20 mg/kg ritonavir administration. Rats were
observed immediately, at 15 min, 2 hr, and daily thereaf-
ter for signs of distress.
Kaolin and food pellets were weighed to the nearest 0.1 g
and placed in containers within the cage each morning.
The kaolin and food remaining from the previous day
were carefully collected, dried for 72 hr and weighed.
Daily kaolin intake and food intake were measured for 5
days following the first ritonavir treatment.
Blood sample collection
In some experiments, blood samples were collected for
the measurement of plasma naltrexone level, an indicator
of possible demethylation of methylnaltrexone [24]. The
rat was restrained and the tail vein was exposed. The tail
was dipped in warm water to help dilate the vessel. A
small rubber band was placed around the base of the tail.
Blood samples were collected using a microhematocrit
tube inserted into the hub of a small needle that was
placed into the vein. Blood samples were collected at 0,
10, 20, 30, 60, 90, or 120 min after the first dose of meth-
ylnaltrexone.
Chemical structures of naltrexone and methylnaltrexone Figure 1
Chemical structures of naltrexone and methylnal-
trexone.
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Measurement of naltrexone and methylnaltrexone 
concentrations
Plasma naltrexone and methylnaltrexone levels were
determined by high performance liquid chromatography
(HPLC) adapted from a previously reported method [25].
Naltrexone and methylnaltrexone were separated from
plasma by the solid phase extraction (SPE) technique.
Plasma samples (100 to 200 μl) diluted in water were
passed through SPE columns (Varian CBA columns, 100
mg, Harbor City, CA) that had been conditioned by n-
propanol and water. The analytes were eluted from the
columns by the mixture of n-propanol and trifluoroacetic
acid (25 mM) in an aqueous solution prepared in 2:1 pro-
portion. The eluate was evaporated to dryness in a stream
of nitrogen at 55°C. The residue was reconstituted in the
mobile phase, filtered through the nylon HPLC syringe fil-
ter and subjected to analysis. In HPLC analysis, an electro-
chemical detector has high sensitivity for automated,
analytical chromatography of electroactive compounds.
The HPLC system (Shimadzu Corporation, Kyoto, Japan)
and electrochemical detector (ESA Coulochem, model
5100A, Chelmsford, MA) consisted of an LC-10AD pump,
SCL-10A system controller, and SIL-10A auto injector
equipped with sample cooler. The electrochemical detec-
tor worked at the following settings: detector 1, +360 mV,
detector 2, +600 mV, guard cell +650 mV. Data were col-
lected using EZChrom 2-2 HPLC software. In the mobile
phase we used sodium phosphate 30 mM, sodium acetate
20 mM, methanol 6%, tetrahydrofuran 1% at pH 4.2. The
system was calibrated daily in the range of 5 to 100 ng/
mL. The practical limit of detection for plasma samples
was approximately 2 ng/mL (100 pg/injection).
Statistical analysis
Data were analyzed with a two-way analysis of variance
(ANOVA) with group and time as the two factors. Statisti-
cal significance was considered at P < 0.05.
Results
Effects of naloxone on ritonavir-induced nausea and 
vomiting
In rats treated with saline, less than 1.0 g kaolin was con-
sumed daily during 5 consecutive days. After oral ritonavir
doses of 10 and 20 mg/kg, kaolin consumption increased
significantly at 24 to 48 hr in a dose-related manner (Fig.
2; P < 0.01 comparing the area under the curve or AUC).
At 30 mg/kg, kaolin intake did not increase further, and
thus, the ritonavir dose used for this study was 20 mg/kg.
Dose-related effects of pretreatment with ritonavir on kaolin intake Figure 2
Dose-related effects of pretreatment with ritonavir on kaolin intake. Rats treated with saline only consumed < 1.0 g/
day of kaolin during 5 consecutive days (0, 24, 48, 72, 96, and 120 hr). Ritonavir doses at 10 and 20 mg/kg significantly increased 
kaolin consumption at 24 to 48 hr in a dose-related manner (P < 0.01). Data are presented as mean ± SEM. n = 6 per group.AIDS Research and Therapy 2009, 6:19 http://www.aidsrestherapy.com/content/6/1/19
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Fig. 3 shows that the ritonavir-induced increase in kaolin
intake was attenuated by 0.1 or 0.3 mg/kg pretreatment
with naloxone. The AUC for kaolin intake from time 0 to
120 hr, vehicle plus vehicle was 87 ± 8.1 g￿hr, naloxone
0.3 mg/kg plus vehicle was 86 ± 9.2 g￿hr, vehicle plus
ritonavir was 351 ± 18.2 g￿hr, naloxone 0.1 mg/kg plus
ritonavir was 264 ± 16.7 g￿hr, and naloxone 0.3 mg/kg
plus ritonavir was 205 ± 11.3 g￿hr (Fig. 4; P < 0.01).
With naloxone 0.3 mg/kg alone, kaolin intake was not sig-
nificantly affected (Fig. 4). In all test groups, food intake
was not significantly affected.
Effects of methylnaltrexone on ritonavir-induced nausea 
and vomiting
Effects of pretreatment with methylnaltrexone on kaolin
intake after ritonavir are shown in Fig. 5. Kaolin intake
induced was attenuated by methylnaltrexone in a dose-
dependent manner. The AUC for kaolin intake from time
0 to 120 hr, vehicle plus vehicle was 92 ± 8.6 g￿hr, vehicle
plus ritonavir was 360 ± 15.7 g￿hr, methylnaltrexone 0.3
mg/kg plus ritonavir was 302 ± 13.2 g￿hr, methylnaltrex-
one 1.0 mg/kg plus ritonavir was 242 ± 14.9 g￿hr, and
methylnaltrexone 3.0 mg/kg plus ritonavir was 168 ± 11.5
g￿hr (Fig. 6; P < 0.01).
With methylnaltrexone 3.0 mg/kg alone, kaolin intake
was not significantly affected (Fig. 6). In all test groups,
food intake was not significantly affected.
HPLC analysis of naltrexone
No detectable naltrexone level was found in association
with methylnaltrexone 3.0 mg/kg. In contrast, methylnal-
trexone levels were detected after it was administered.
Representative chromatograms are shown in Fig. 7.
Discussion
Protease inhibitors are efficacious antiretroviral agents
that produce several adverse effects, especially nausea and
vomiting. To date, the mechanism by which protease
inhibitors cause nausea or vomiting has not been investi-
gated. Considering that compliance with treatment is a
pre-requisite for effective antiviral therapy in patients with
AIDS, drug-induced adverse effects that inhibit compli-
ance should be treated. Treatment with conventional anti-
emetics, usually in combination, can partially decrease
ritonavir-induced nausea and vomiting. Ondansetron, a
5-HT3 antagonist, has been used in refractory cases of nau-
sea and vomiting in AIDS patients, in combination with
other anti-emetics [14,19,20]. Whether endogenous opio-
ids contribute to the adverse effects in the gut is unknown.
Effects of pretreatment with naloxone on kaolin intake induced by ritonavir in rats Figure 3
Effects of pretreatment with naloxone on kaolin intake induced by ritonavir in rats. Ritonavir-induced increase in 
kaolin intake was attenuated with naloxone in a dose-related manner (P < 0.01). Data are presented as mean ± SEM. n = 6 per 
group. NLX, naloxone; RIT, ritonavir.AIDS Research and Therapy 2009, 6:19 http://www.aidsrestherapy.com/content/6/1/19
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In this study, we evaluated the effects of opioid receptor
antagonists on ritonavir-induced nausea and vomiting.
Naloxone reduced ritonavir-induced nausea and vomit-
ing. A non-selective opioid antagonist such as naloxone,
however, compromises opioid analgesia [17]. Therefore,
treating ritonavir-induced emesis with naloxone may not
be clinically applicable to patients who take opioid medi-
cation for AIDS-related pain, which can result from the
virus itself, various forms of treatment, opportunistic
infections and cancers [26].
Methylnaltrexone (or N-methylnaltrexone bromide) is a
quaternary derivative of opioid antagonist, naltrexone
(Fig. 1). As tertiary compounds, antagonists such as
naloxone, naltrexone and nalmaphene are fairly lipid sol-
uble and cross the blood-brain barrier easily. Addition of
the methyl group to naltrexone forms a compound with
greater polarity and lower lipid solubility. Thus, methyln-
altrexone has restricted access to the blood-brain barrier
and decreases the constipating effects of adverse effects of
opioid pain medications. Because these effects are medi-
ated by peripherally located receptors, the analgesic
effects, which are mediated at receptors in the central
Area under the curve (AUC) for kaolin intake from time 0 to  120 hr Figure 4
Area under the curve (AUC) for kaolin intake from 
time 0 to 120 hr. Naloxone significantly reduced kaolin 
intake induced by ritonavir (P < 0.01 compared to vehicle). 
Naloxone 0.3 mg/kg alone did not affect kaolin intake. Data 
are presented as mean ± SEM. RIT, ritonavir 20 mg/kg; 
NLX0.1, naloxone 0.1 mg/kg; NLX0.3, naloxone 0.3 mg/kg.
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Effects of pretreatment with methylnaltrexone on kaolin intake induced by ritonavir in rats Figure 5
Effects of pretreatment with methylnaltrexone on kaolin intake induced by ritonavir in rats. Ritonavir-induced 
increase in kaolin intake was attenuated with methylnaltrexone in a dose-related manner (P < 0.01). Data are presented as 
mean ± SEM. n = 6–7 per group. MNTX, methylnaltrexone; RIT, ritonavir.AIDS Research and Therapy 2009, 6:19 http://www.aidsrestherapy.com/content/6/1/19
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nervous system, are spared [27]. In this study methylnal-
trexone significantly attenuated non-opioid, protease
inhibitor-induced nausea and vomiting. Methylnaltrex-
one may have clinical value in treating protease inhibitor-
induced emesis without affecting analgesia.
A rat pica model was used to evaluate the symptoms of
nausea and emesis. Rats exposed to a variety of emetic
stimuli feed on non-nutritive substances like clay, a phe-
nomenon called pica behavior. Pica in rats is thus analo-
gous to nausea and vomiting in humans and other species
[11,13]. Pica in rats is mediated by mechanisms and
receptors involving serotonin and dopamine, similar to
those in humans and other species [12,13]. The model has
been used extensively and validated in several studies
researching anti-emetic drugs [12,16]. A dose-dependent
pica response induced by ritonavir has already been dem-
onstrated [14]. In this study, we used the pica model to
confirm that treatment with methylnaltrexone signifi-
cantly reduced ritonavir-induced pica.
In rodents, methylnaltrexone may be partially metabo-
lized via demethylation as measured by the exhaled 14CO2
breath test [24]. However, systemic methylnaltrexone
administration did not antagonize morphine-induced
analgesia in rats subjected to the radiant-heat tail-flick
assay, and morphine-induced reduction in gastrointesti-
nal tract movement was antagonized by the compound in
a dose-related manner [28]. In our study, we used HPLC
to measure plasma naltrexone levels after methylnaltrex-
one administration and no detectable naltrexone level
was found with the highest methylnaltrexone dose. In a
Representative HPLC chromatograms of methylnaltrexone  and naltrexone in plasma samples Figure 7
Representative HPLC chromatograms of methylnal-
trexone and naltrexone in plasma samples. (A), a chro-
matogram of a standard plasma extract of methylnaltrexone 
(100.0 ng/mL) and naltrexone (50.0 ng/mL); (B), 92.5 ng/mL 
methylnaltrexone was detected after 3.0 mg/kg administra-
tion; (C), a gradually reduced methylnaltrexone level (4.7 ng/
mL) was detected as time elapsed. At all measured time 
points, no naltrexone level was detected, as shown in (B) and 
(C). MNTX, methylnaltrexone; NTX, naltrexone.

Area under the curve (AUC) for kaolin intake from time 0 to  120 hr Figure 6
Area under the curve (AUC) for kaolin intake from 
time 0 to 120 hr. Methylnaltrexone significantly reduced 
kaolin intake induced by ritonavir (P < 0.01 compared to 
vehicle). Data are presented as mean ± SEM. RIT, ritonavir 
20 mg/kg; MNTX0.3, methylnaltrexone 0.3 mg/kg; MNTX3.0, 
methylnaltrexone 3.0 mg/kg.
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separated analytical study, a more sensitive LC/MS/MS
assay was also used to detect any possible demethylation
of methylnaltrexone for up to 6 hr after the first dose of
the compound, and results showed that levels of naltrex-
one were below the limit of detection (unpublished data),
suggesting that naltrexone did not play a pharmacody-
namic role in our experimental paradigm.
Pain is a major issue for people living with HIV and AIDS,
and opioids are widely prescribed for non-cancer and can-
cer pain conditions [29,30]. In this study, our data suggest
that opioid receptor antagonists contribute to relieving
protease inhibitor-induced gastrointestinal adverse
effects, and thus, methylnaltrexone may have a clinical
utility in reducing nausea and vomiting in AIDS patients
who take ritonavir. In addition, besides the compound's
anti-emetic activity in HIV therapy, methylnaltrexone is
also effective in counteracting opioid-induced bowel dys-
function in these AIDS patients without interfering with
pain control.
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